Tandem Diabetes Care (TNDM) Capital Expenditures (2013 - 2026)

Tandem Diabetes Care's Capital Expenditures history runs 14 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• Quarterly Capital Expenditures rose 111.4% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (up 2135.99% YoY) and the FY2025 annual result came in at $19.9 million, up 2333.82% from the prior year.
• Capital Expenditures was $6.3 million for Q1 2026 at Tandem Diabetes Care, down from $6.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $12.2 million in Q3 2025 and bottomed at -$17.1 million in Q4 2024.
• A 5-year average of $1.7 million and a median of $3.0 million in 2025 frame the typical range for Capital Expenditures.
• Peak annual rise in Capital Expenditures reached 3323.53% in 2022, while the deepest fall reached 5800.0% in 2022.
• Tandem Diabetes Care's Capital Expenditures stood at $247000.0 in 2022, then soared by 600.4% to $1.7 million in 2023, then plunged by 1085.84% to -$17.1 million in 2024, then jumped by 139.2% to $6.7 million in 2025, then decreased by 6.24% to $6.3 million in 2026.
• Business Quant data shows TNDM's Capital Expenditures at $6.3 million in Q1 2026, $6.7 million in Q4 2025, and $12.2 million in Q3 2025.